Jaume Ayguasanosa

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa et al. · The Lancet · 2023 · 77 citations · Full text

Thrombopoiesis, Autoimmune Disease, Blood Platelet +11

SPARTA clinical trial design: Exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency

Susan C. Sorrells, Sandra Camprubí, Rhonda Griffin et al. · Respiratory Medicine · 2015 · 43 citations · Full text

A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations

Guntis Karelis, Rodica Bălașa, Jan De Bleecker et al. · European Neurology · 2019 · 28 citations · Full text

A Prospective, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Fibrin Sealant Grifols as an Adjunct to Hemostasis as Compared to Cellulose Sheets in Hepatic Surgery Resections

Miloš Bjelović, Jaume Ayguasanosa, Robin D. Kim et al. · Journal of Gastrointestinal Surgery · 2018 · 20 citations · Full text

Tissue Engineering, Cellulose Sheets, Hepatology +11

A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of Fibrin Sealant Grifols as an adjunct to hemostasis compared with manual compression in vascular surgery

Dragoslav Nenezić, Jaume Ayguasanosa, G. Menyhei et al. · Journal of Vascular Surgery · 2019 · 19 citations · Full text

Manual Compression, Thrombosis, Fibrin Sealant Grifols +9